134 related articles for article (PubMed ID: 28395195)
21. Water-soluble DNA minor groove binders as potential chemotherapeutic agents: synthesis, characterization, DNA binding and cleavage, antioxidation, cytotoxicity and HSA interactions.
Fu XB; Liu DD; Lin Y; Hu W; Mao ZW; Le XY
Dalton Trans; 2014 Jun; 43(23):8721-37. PubMed ID: 24770345
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, structure, protein binding of Cu(II) complexes with a tridentate NNO Schiff-base ligand.
Li M; Huang S; Ye C; Xie Y
Spectrochim Acta A Mol Biomol Spectrosc; 2015; 150():290-300. PubMed ID: 26056979
[TBL] [Abstract][Full Text] [Related]
23. Is the Sudlow site I of human serum albumin more generous to adopt prospective anti-cancer bioorganic compound than that of bovine: A combined spectroscopic and docking simulation approach.
Joshi R; Jadhao M; Kumar H; Ghosh SK
Bioorg Chem; 2017 Dec; 75():332-346. PubMed ID: 29096094
[TBL] [Abstract][Full Text] [Related]
24. Oxindole-Schiff base copper(II) complexes interactions with human serum albumin: spectroscopic, oxidative damage, and computational studies.
da Silveira VC; Caramori GF; Abbott MP; Gonçalves MB; Petrilli HM; da Costa Ferreira AM
J Inorg Biochem; 2009 Oct; 103(10):1331-41. PubMed ID: 19595461
[TBL] [Abstract][Full Text] [Related]
25. Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment.
Zhang Z; Zhang J; Jiang M; Zhao L; Li S; Sun H; Yang F; Liang H
Mol Pharm; 2020 Apr; 17(4):1405-1414. PubMed ID: 32096645
[TBL] [Abstract][Full Text] [Related]
26. Affinity of a mononuclear monofunctional anticancer Pt(II) complex to human serum albumin: a spectroscopic approach.
Chen Z; Zhang S; Zhang J
Biometals; 2015 Dec; 28(6):1031-41. PubMed ID: 26475326
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.
Khan S; Malla AM; Zafar A; Naseem I
PLoS One; 2017; 12(8):e0181783. PubMed ID: 28763458
[TBL] [Abstract][Full Text] [Related]
28. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
29. DNA damaging, cell cytotoxicity and serum albumin binding efficacy of the rutin-Cu(ii) complex.
Roy AS; Tripathy DR; Samanta S; Ghosh SK; Dasgupta S
Mol Biosyst; 2016 Apr; 12(5):1687-701. PubMed ID: 27035097
[TBL] [Abstract][Full Text] [Related]
30. Mixed-ligand mononuclear copper(II) complex: crystal structure and anticancer activity.
Qin XY; Liu YN; Yu QQ; Yang LC; Liu Y; Zhou YH; Liu J
ChemMedChem; 2014 Aug; 9(8):1665-71. PubMed ID: 24839939
[TBL] [Abstract][Full Text] [Related]
31. Cell cytotoxicity and serum albumin binding capacity of the morin-Cu(ii) complex and its effect on deoxyribonucleic acid.
Roy AS; Samanta SK; Ghosh P; Tripathy DR; Ghosh SK; Dasgupta S
Mol Biosyst; 2016 Aug; 12(9):2818-33. PubMed ID: 27345944
[TBL] [Abstract][Full Text] [Related]
32. Mixed ligand copper(II) complexes of N,N-bis(benzimidazol-2-ylmethyl)amine (BBA) with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity.
Loganathan R; Ramakrishnan S; Suresh E; Riyasdeen A; Akbarsha MA; Palaniandavar M
Inorg Chem; 2012 May; 51(10):5512-32. PubMed ID: 22559171
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, DNA/HSA Interaction Spectroscopic Studies and In Vitro Cytotoxicity of a New Mixed Ligand Cu(II) Complex.
Gan Q; Fu X; Chen W; Xiong Y; Fu Y; Chen S; Le X
J Fluoresc; 2016 May; 26(3):905-18. PubMed ID: 26961845
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and Structure of a Ternary Copper(II) Complex with Mixed Ligands of Diethylenetriamine and Picrate: DNA/Protein-Binding Property and In Vitro Anticancer Activity Studies.
Shi YN; Zheng K; Zhu L; Li YT; Wu ZY; Yan CW
J Biochem Mol Toxicol; 2015 May; 29(5):221-33. PubMed ID: 25652782
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization and interaction studies of copper based drug with Human Serum Albumin (HSA): spectroscopic and molecular docking investigations.
Tabassum S; Al-Asbahy WM; Afzal M; Arjmand F
J Photochem Photobiol B; 2012 Sep; 114():132-9. PubMed ID: 22750083
[TBL] [Abstract][Full Text] [Related]
36. Designing Prodrugs Based on Special Residues of Human Serum Albumin.
Gou Y; Yang F; Liang H
Curr Top Med Chem; 2016; 16(9):996-1008. PubMed ID: 26303424
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of enantiomeric (R)- and (S)-copper(II) and diorganotin(IV)-based antitumor agents: their in vitro DNA binding profile, cleavage efficiency and cytotoxicity studies.
Arjmand F; Muddassir M; Yousuf I
J Photochem Photobiol B; 2014 Jul; 136():62-71. PubMed ID: 24857791
[TBL] [Abstract][Full Text] [Related]
38. Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects.
Basken NE; Green MA
Nucl Med Biol; 2009 Jul; 36(5):495-504. PubMed ID: 19520290
[TBL] [Abstract][Full Text] [Related]
39. Structure and biological properties of mixed-ligand Cu(II) Schiff base complexes as potential anticancer agents.
Gou Y; Li J; Fan B; Xu B; Zhou M; Yang F
Eur J Med Chem; 2017 Jul; 134():207-217. PubMed ID: 28415010
[TBL] [Abstract][Full Text] [Related]
40. The Cu/ligand stoichiometry effect on the coordination behavior of aroyl hydrazone with copper(II): Structure, anticancer activity and anticancer mechanism.
Deng J; Gou Y; Chen W; Fu X; Deng H
Bioorg Med Chem; 2016 May; 24(10):2190-8. PubMed ID: 27056799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
